Molecular Assessment of Artemisinin Resistance Markers in Eastern and Western Border Areas of Myanmar

N/ACompletedNCT02198573

Myat Htut Nyunt91 enrolled

Overview

* Artemisinin resistance have been documented in Myanmar and Myanmar artemisinin resistance containment measures have been launched since 2009-2010. * It is important to monitor the spread and magnitude of artemisinin resistant malaria in Myanmar. * So, day-3 surveillance study have been conducted. * Recently artemisinin resistant molecular marker, K13 have been identified and it was used as a tool in this study.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Day-3 Positive of Parasitaemia Prevalence of Drug Resistance Gene Mutation

Eligibility

Sex: ALLMin age: 2 Years

Medical Language ↔ Plain English

Inclusion Criteria: * confirmed uncomplicated falciparum malaria patients. * age \>2 years * box sex * given informed consent Exclusion Criteria: * severe malaria * did not give informed consent * others diseases

Locations (1)

Dr. Myat Phone Kyaw

Yangon, Yangon, Burma

Outcomes

Primary Outcomes

day-3 parasite positivity

All of the enrolled patients were monitored with appropriate care up to third day and take the samples on day-3.

Time frame: 3 days

Secondary Outcomes

Prevalence of the drug resistance marker

By using the dried blood spots, drug resistance markers were detected by molecular method.

Time frame: up to day-3

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.